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Abstract
Arbidol (ARB) is an antiviral compound that was originally proven effective for treatment of
influenza and several other respiratory viral infections. The broad spectrum of ARB anti-viral
activity led us to evaluate its effect on hepatitis C virus (HCV) infection and replication in cell
culture. Long-term ARB treatment of Huh7 cells chronically replicating a genomic length genotype
1b replicon resulted in sustained reduction of viral RNA and protein expression, and eventually
cured HCV infected cells. Pre-treatment of human hepatoma Huh7.5.1 cells with 15 μM ARB for
24 to 48 hours inhibited acute infection with JFH-1 virus by up to 1000-fold. The inhibitory effect
of ARB on HCV was not due to generalized cytotoxicity, nor to augmentation of IFN antiviral
signaling pathways, but involved impaired virus-mediated membrane fusion. ARB's affinity for
membranes may inhibit several aspects of the HCV lifecycle that are membrane-dependent.
Background
There are presently limited therapeutic options for
patients with chronic hepatitis C, especially those who
have failed interferon (IFN) based modalities. The HCV
replicon system, originally described by Lohmann and
colleagues [1], has proven to be an effective in vitro model
for pre-clinical evaluation and large-scale screening of
new anti-HCV compounds (reviewed in [2]. In addition
to the testing of novel anti-HCV compounds, the replicon
system has also facilitated the characterization of existing
compounds that show antiviral activity against other
viruses [3,4]. Drugs that target viral proteins, such as the
NS3-4a protease, are presumed to be less toxic and more
specific. However, it is now clear that the use of these com-
pounds can lead to drug-resistant viral variants, at least in
vitro [5]. Another group of antivirals with broad-spectrum
activity impact cellular metabolic pathways such as inter-
feron production, or interfere with cellular functions or
critical steps in virus-cell interactions, possibly exerting
higher cell toxicity with little, if any, virus resistance.
Other broad-spectrum antiviral agents target rate-limiting
events in viral replication cycle such as envelope protein
glycosylation, processing and folding [6], or viral-cell
membrane fusion during viral uncoating or assembly
(reviewed in [6,7]).
One example of the latter group compounds is arbidol
(ARB; ethyl-6-bromo-4-[(dimethylamino)methyl]-5-
hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-car-
boxylate hydrochloride monohydrate), a Russian-made
broad-spectrum antiviral that had been shown to inhibit
the fusion of influenza A and B viruses within endosomes
[8]. An acidic environment (pH 5.0) is a strict prerequisite
for influenza virus-induced fusion, and even a slight
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also been shown to exert antiviral activity against other
pH-dependent viruses, such as hepatitis B virus [10], and
rhinovirus 14 (reviewed in [7]). Since ARB is a weak base,
it might elevate endosomal pH and abrogate virus-endo-
some fusion. Since optimal HCV envelope protein fusion
with cell membranes requires low pH and the fusion proc-
ess may occur within endosomes [11-14], ARB might
potentially exert an antiviral activity on HCV as well.
However, since ARB was shown to inhibit various pH-
independent viruses such as the human respiratory syncy-
tial virus and the parainfluenza virus 3 [7], ARB could
affect membrane interactions that are necessary for virus
replication. Alternatively, ARB has been claimed to stimu-
late the production of interferon [7,8], a well-known and
potent inhibitor of HCV replication [15]. Taken together,
these observations prompted us to investigate ARB activity
on HCV lifecycle, and more specifically on HCV replica-
tion. We therefore studied the effects of ARB on HCV RNA
and protein expression using primary productive HCV
infection or persistent non-productive HCV infection in
cultured replicon cells. We report that ARB inhibits acute
and chronic HCV replication independently of activation
of innate antiviral signaling pathways. Instead, we show
that ARB antiviral activity towards HCV is due to a direct
effect of ARB on virus-cell membrane interactions.
Results
Effects of ARB on cell viability
Huh7, Huh7.5.1 or FL-NEO cells were treated with ARB
concentrations in the range of 2 μg/ml (3.8 μM) to 15 μg/
ml (28.2 μM). These doses of ARB were previously found
to exert anti-viral effects (Brooks et al., 2004). Cell viabil-
ity was measured by ATP fluorescence. As shown in Figure
1, the concentration of ARB that reduced FL-Neo and
Huh7 viability by 50% (CC50) was 8.0 and 12.5 μg/ml,
respectively. FL-Neo cells were slightly more sensitive to
the effects of ARB, an effect that could be due to increased
cell stress as a result of high level expression and replica-
tion of the entire HCV genome. The CC50 for Huh7.5.1
cells was similar to Huh7 cells (data not shown). From
these observations, we treated FL-Neo replicon cells with
6 μg/ml ARB and Huh7 and Huh7.5.1 cells with 8 μg/ml
ARB in subsequent experiments.
ARB inhibits chronic HCV replication
FL-Neo cells were cultured in the presence of 6 μg/ml of
ARB from 3 days to several weeks, with weekly analysis of
viral proteins expression by Western blot. Cells were fed
with ARB daily since its half-life in cultured cells is about
18 hours [16]. At this concentration, cells did not appear
to be stressed, nor did the cells display significant cytotox-
icity during regular cell passage and trypan blue counting.
Figure 2A presents HCV core and NS5A protein expression
data and shows that the anti-viral effect of ARB appeared
during the second week of treatment. HCV core protein
became virtually undetectable after 3 weeks of ARB treat-
ment onwards. The level of HCV NS5A and core protein
expression after 3 weeks of ARB treatment was similar to
the inhibition of viral proteins following 48 hours of IFN-
α treatment. HCV RNA levels in ARB-treated cells also
gradually declined (Figure 2B) until they dropped to
0.45% of that of untreated FL-Neo cells on the ninth week
post-treatment. After 10 weeks of ARB treatment, cells
were split in two halves: one was left in Huh7 medium
(lacking G418) with ARB and the other transferred to
G418-supplemented medium lacking ARB. In the pres-
ence of G-418, FL-Neo cells displayed extensive cytopathic
effect. After two more weeks of culture, G-418-treated FL-
Neo cells perished, presumably due to the loss of replicon
RNA and the concomitant loss of neomycin resistance.
The other half of ARB-treated, G418-free culture was
extracted for RNA and subjected to real time RT-PCR. HCV
RNA was undetectable by real time RT-PCR (data not
shown), indicating that after 10 weeks of ARB treatment
the FL-Neo cells were cured of HCV infection, with no
HCV rebound in the following two weeks (data not
shown).
ARB inhibits acute HCV infection
Huh7.5.1 cells were seeded in 6-well plates at 0.5 × 106
cells/well and infected the next day with a JFH-1 viral
stock at a multiplicity of infection of 0.02. ARB (8 μg/ml)
was added to cells 48 hours (-48 h) or 24 hours (-24 h)
before infection, at the time of infection (0 hrs) and 24
hours (+24 h) or 48 hours (+48 h) post-infection. At 72
hours post-infection the extracellular virus was collected
for infectious virus titration, and cells were lysed for West-
ern blot analysis of HCV core protein expression. The
results of protein analysis showed that ARB had the most
pronounced inhibitory effect in pre-treated cells (24 and
Determination of CC50 for ARBFigu e 1
Determination of CC50 for ARB. FL-Neo or Huh7 cells 
were treated with increasing concentrations of ARB for 72 
hours and assessed for viability using the ATPlite assay. Each 
point on the curve represents the average of six replicates.Page 2 of 9
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observed if ARB was added at the time of infection. ARB
did not exert any antiviral effects when it was added 24 or
48 hrs post-infection (Figure 3A and 3B). These results
were in agreement with yields of infectious JFH-1 virus,
measured via immunofluorescent detection of the HCV
NS5A protein by a focus forming assay [17] (Figure 3C).
Figure 3D demonstrates that ARB inhibited infectious
Arbidol inhibits chronic HCV replicationFigure 2
Arbidol inhibits chronic HCV replication. FL-Neo replicon cells were passaged without G418 in the presence of 6 μg/ml 
(11 μM) ARB for 3 days (lane 3d), or 1, 2, 3 or 4 weeks (lanes 1w to 4w). Huh7 cells, as a control for non HCV-replicating 
cells, were treated (lane ARB +) or not (lane ARB -) at 6 μg/ml for 3 days. The rightmost lane labeled ARB- represents proteins 
from control FL-Neo cells, treated without ARB for 4 weeks. FL-Neo cells were separately treated with 100 U/ml IFN-α for 
48 h (lane IFN +) or not (lane IFN -). Cells were then lysed and treated as described in Materials and Methods. Ten μg of total 
cell protein of each sample extract were submitted to SDS-PAGE, followed by western blotting with murine monoclonal anti-
bodies to NS5A or core proteins, or polyclonal antiserum to GAPDH.Page 3 of 9
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cells 48 hours prior to infection, and a 100-fold HCV titer
reduction when the drug was given 24 hrs before infec-
tion. Addition of ARB at the same time or 24–48 hours
after JFH-1 infection did not significantly affect virus
yields (Figure 3C and 3D). The data indicate that ARB
inhibits acute HCV infection when administered prophy-
lactically.
ARB does not affect RIG-I and IFN signaling pathways
Since IFN is known to inhibit HCV replication, we deter-
mined the effects of ARB on innate antiviral signal trans-
duction pathways in FL-Neo and Huh7 cells. We
measured activation of the IFN-β promoter by retinoic
acid inducible gene 1 (RIG-I), a key factor in double
stranded RNA signaling in response to HCV infection
[18]. We also measured basal and IFN-α induced ISRE
transcription, a measure activation of Jak-Stat pathway
activation via the ISGF-3 transcription factor, which is a
complex of Stat1-Stat2-IRF9 proteins [19]. ISRE activation
occurs downstream of IFN-β activation during virus infec-
tion [20]. As shown in Figure 4A, transfection of FL-Neo
replicon and Huh7 cells with RIG-N, a constitutively
active mutant of RIG-I [21], caused robust induction of
IFN-β transcription, as compared to cells that expressed
control green fluorescent protein (GFP). Addition of ARB
to cells did not modify the basal level of RIG-N-induced
IFN-β transcription. Rather, ARB caused a dose-dependent
inhibition of IFN-β transcription in all conditions. Figure
4B demonstrates that IFN-α treatment of FL-Neo and
Huh7 cells activates ISRE transcription, and that ARB dose
dependently inhibits basal and IFN-induced ISRE pro-
moter activity. Moreover, treatment of Huh7 and
Huh7.5.1 cells with ARB did not induce phosphorylation
on the conserved tyrosine amino acid at position 701 of
the Stat1 protein (Figure 4C), an essential requirement
and indicator of IFN signaling through the Jak-Stat path-
way [19]. As a control, IFN treatment of cells for 20 or 60
minutes induced robust Stat1-Y701 phosphorylation in
both cell types. Finally, incubation of FL-Neo cells with
ARB inhibits acute HCV infectionFigure 3
ARB inhibits acute HCV infection. A: HCV core protein inhibition in ARB-pretreated Huh7.5.1 cells. Cells were pre-incu-
bated with 8 μg/ml ARB for 24 (-24 h) or 48 (-48 h) hours prior to infection with JFH-1 (moi 0.02) for 72 hours. Cells were 
also treated with ARB at the time of JFH-1 infection (0 h), and treated 24 (+24 h) and 48 (+48 h) hours post-infection. Equal 
amounts of total protein were probed for HCV core with a monoclonal antibody. Blots were stripped and reprobed for 
GAPDH expression to verify equal loading of protein in all lanes. B: quantitation of HCV core protein expression. Blots in 
panel A were scanned and pixel intensity measured using Image J software. Data were normalized to GAPDH levels. C: Sup-
pression of infectious JFH-1 yields in ARB-pretreated cells. Cell-free supernatants from the experiment described in panel A 
were quantitated for infectious virus by the focus-forming assay as described in the Materials and Methods. Green foci depict 
NS5A expressing cells. D: Quantitation of JFH-1 titers from panel C. Supernatants from control and ARB treated cells were 
serially diluted and the titer of virus determined using the focus-forming assay. Titers were calculated by counting the number 
of foci and correcting for the dilution factor, as described previously [17].Page 4 of 9
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ISGs Stat1 and Stat2 (Figure 4D). In contrast, treatment of
cells with IFN-α for 24 hours induced Stat1 and Stat2 pro-
teins. Collectively, the data indicate that ARB does not
induce an IFN antiviral response in hepatocyte cultures
that could account for the inhibition of HCV replication
by ARB.
ARB inhibits HCV membrane fusion
As mentioned earlier, ARB exerts its antiviral activity on
influenza virus partly through the inhibition of viral
membrane fusion in the endosome. Since the optimal pH
for HCV fusion is at 5.5 [13,14], we reasoned that ARB
might similarly affect HCV fusion. This was tested in our
recently developed in vitro fusion assay using fluores-
cently-labeled liposomes and HCV pseudoparticles
(HCVpp) harboring HCV E1/E2 glycoproteins at their sur-
face, and assembled around a retroviral core [14,22]. As
shown in Figure 5A, ARB displayed a dose-dependent
inhibition of HCVpp-mediated lipid mixing, with fusion
becoming virtually undetectable at a concentration 1 μg/
ml ARB. This was observed for HCVpp derived from two
different HCV genotype 1b isolates (AY734975 and
AF333324). As a positive control, ARB also completely
inhibited the fusion of pseudoparticles bearing the influ-
enza virus hemagglutinin (HA) protein (Fig. 5B). The
inhibition was observed immediately after addition of
ARB to the cuvette, and was similar when either HCVpp-
ARB does not induce IFN antiviral responsesFigure 4
ARB does not induce IFN antiviral responses. A, ARB does not induce RIG-I dependent signaling. FL-Neo replicon and 
Huh7 cells were co-transfected with IFNB-luciferase and GFP or IFNB-luciferase and constitively active RIG-N expressing plas-
mids for 3 hours. Transfection mixtures were then removed and cells were incubated with medium containing the indicated 
concentrations of ARB. Luciferase activity was measured 24 hours later. B, ARB does not induce ISRE transcription. FL-Neo 
and Huh7 cells were transfected with ISRE-luciferase reporter plasmids for 3 hours. Transfection mixtures were then removed 
and cells were incubated with medium containing the indicated concentrations of ARB for 20 hours. Cells were then treated or 
not treated with 100 U/ml of IFN-α (Roferon) for 4 hours before luciferase activity was measured. C, ARB does not induce 
Stat1 phosphorylation on the conserved tyrosine amino acid at position 701. Huh7 or Huh7.5.1 cells were treated with the 
indicated amounts of ARB and whole cell protein extracts were harvested 20 and 60 minutes later. Cells were also treated 
with 500 units per milliliter of IFN-α, or as a negative control for possible solvent effects, an equivalent volume of ethanol 
(Ctrl). The position of Stat1-Y01 is indicated with arrows. D, ARB does not induce IFN stimulated gene expression. FL-Neo 
cells were treated with 6 μg/ml ARB for 1 to 4 days, or treated with 100 U/ml IFN-α for 24 hours. Whole cell protein extracts 
were probed for Stat1, Stat2, and GAPDH protein levels.Page 5 of 9
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over, since our fusion assay is based upon the use of plain
lipid vesicles, which do not contain cell surface receptors
for HCV, the inhibition is probably not due to a direct
effect of ARB on the HCV glycoproteins E1 and/or E2.
Rather, the data suggest that the effect of ARB on virus/
liposome interactions occurs at the membrane level. This
is strengthened by the observation that ARB exerts a simi-
lar fusion inhibiting effect on HCVpp harboring glycopro-
teins from other genotypes as well (Pécheur EI, Boriskin Y,
Lavillette D, Roberts M, Cosset FL, Polyak SJ, manuscript
in preparation). Taken together, the data suggest that ARB
interacts with membranes and likely perturbs stages of the
HCV lifecycle that are membrane-dependent.
Discussion
The advent of HCV replicon cultures [1,23] and in partic-
ular, productive replicon infection systems [17,24,25],
has given tremendous opportunities for preclinical assess-
ment of anti-HCV compounds. As a result, a number of
specific viral inhibitors are already in various phases of
clinical trials (reviewed in [5]). Among the non-specific,
broad-spectrum antivirals, a few well-known over-the-
counter drugs have shown inhibitory activity against HCV
in replicon cell cultures [3,4]. This latter group of antivi-
rals can now be extended to include ARB, which exerts
anti-viral activity against acute and chronic HCV replica-
tion.
Based on its chemical structure, ARB may be a pro-drug
which becomes chemically converted into an active drug
by cellular metabolic processes. The pro-drug nature of
ARB may explain its relatively high CC50 values, assum-
ing that the actual ARB metabolite concentration is lower
than that of the ARB pro-drug. The carboxylic acid ester
moiety contained in the structure of ARB may be a sub-
strate for hydrolysis in vivo that leads to the intracellular
accumulation of ARB. The fact that ARB displayed prophy-
lactic activity when administered 24–48 hours before pri-
mary infection, and over several weeks of treatment in
persistent HCV infection, might indicate a prerequisite for
ARB accumulation in intracellular compartments before
antiviral activity is observed. Clearly, additional studies of
ARB and various chemical derivatives are warranted.
Nonetheless, the sustained effect of ARB on persistent
HCV could be of clinical significance since chronic infec-
tion comprises about 75–85% of all hepatitis C cases [26].
Our results suggest that the inhibitory effect of ARB on
HCV is not mediated by stimulation of type 1 IFN signal-
ing pathways. In fact, ARB inhibited antiviral signaling in
FL-Neo and Huh7 cells, an effect which might be attribut-
able to ARB disruption of membrane interactions
required for signal transduction. Instead, ARB's anti-HCV
action appears to be attributable to an inhibitory effect on
viral fusion (Pécheur EI, Boriskin Y, Lavillette D, Roberts,
M, Cosset FL, Polyak SJ, manuscript in preparation). In
Arbidol inhibits HCVpp-mediated lipid mixingFigure 5
Arbidol inhibits HCVpp-mediated lipid mixing. Lipid 
mixing curves of HCVpp genotype 1b (panel A) and of HApp 
(panel B) in the absence or presence of ARB, with R18-
labeled liposomes (representative of 3 separate experi-
ments). Fourty μl of HCVpp-1b (panel A, solid lines repre-
sent 1b-AY for Genbank accession number AY734975, while 
dotted lines are labeled as 1b-AF for Genbank accession 
number AF333324) or HApp (panel B) were added to R18-
labeled phosphatidylcholine:cholesterol liposomes (15 μM 
final lipid concentration), in PBS pH 7.4 at 37°C, with or 
without 1 (ARB 1) or 6 μg/ml (ARB 6) ARB. After a 2-min 
equilibration, lipid mixing was initiated by decreasing the pH 
to 5.0 (time 0), and recorded as R18 fluorescence dequench-
ing as a function of time. The 100% fluorescence was 
obtained by adding 0.1% (v:v; final concentration) Triton X-
100 to the suspension.Page 6 of 9
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the fusion of HCV pseudoparticles from multiple geno-
types with liposomal membranes in a strictly controlled
pH environment of 5.0. This observation makes it
unlikely that ARB inhibits virus replication by increasing
the endosomal pH like other weak bases such as chloro-
quine [27]. Moreover, since HCV fusion takes place
within much wider range (6.3 – 5.0) compared to strictly
HA conformation-sensitive influenza virus fusion [14], if
ARB did induce a basic pH shift, it is predicted that the
shift would be minor and affect the HCV fusion process
minimally. One model for ARB's anti-fusion activity is
that ARB, because of its chemical structure, has a propen-
sity for cell membranes. If ARB intercalates into mem-
branes and adopts a consistent orientation, the formation
of an "ARB cage" could lead to excessive stabilization of
cell membranes, and thereby prevent HCV fusion. Alter-
natively, at the virus level, ARB might block the un-coating
of the membrane during the fusion process. It is also con-
ceivable that ARB could inhibit other aspects of the HCV
life cycle that are dependent on cell membranes. For
example, the HCV replication complex associates with
endoplasmic reticulum membranes to form membranous
webs [28]. The web is formed via the association of HCV
non-structural proteins with ER membranes [29]. Thus,
ARB-induced inhibition of HCV non-structural protein
interactions with organelle membranes might also con-
tribute to suppression of HCV replication. However, at
least in terms of acute infection with JFH-1, the predomi-
nant mechanism of action of ARB is likely to be inhibition
of fusion, since ARB only suppressed JFH-1 infection
when given 24–48 hours prior to infection. On the other
hand, FL-Neo cells were cured of HCV replication follow-
ing several weeks of ARB treatment. Since genomic length
replicons do not produce infectious virus, in these cells,
ARB inhibition of the HCV replication complex associa-
tion with membranes could be the predominant mode of
HCV suppression. Additional studies are required to sort
out these possibilities.
In conclusion, ARB inhibits HCV acute and chronic HCV
infection and replication. The inhibitory effect appears to
be due to the interaction of ARB with membranes and to
subsequent ARB-induced membrane alterations, but the
nature of the membrane modification(s) require further
study.
Materials and methods
Cells, culture media, drug preparation, plasmids
Huh7 and Huh7.5.1 human hepatoma cells were cultured
in Dulbecco's modified Eagle medium (DMEM) contain-
ing 9% fetal calf bovine serum, 1% penicillin-streptomy-
cin-fungizone and 1% nonessential amino acids (all
reagents were from Invitrogen, Carlsbad, CA). FL-Neo
cells are a stable human hepatoma Huh7-derived cell line
harboring autonomously replicating genomic length gen-
otype 1b HCV replicon with adaptive mutations in NS3
(P1496L) and NS5A (S2204I). Huh7 and FL-Neo cells
were obtained from Apath, LLC (St Louis, MO), and
Huh7.5.1 cells were obtained from Francis Chisari [17].
FL-Neo cells were cultured in Huh7 medium supple-
mented with 0.4 mg/ml of G418 (Calbiochem, San
Diego, CA). They were passaged with a 1:10 split and
maintained subconfluent in the course of each experi-
ment. During short- or long-term ARB treatment, FL-Neo
cells were cultured in medium without G418. Control cul-
tures consisting of FL-Neo cells grown in the absence of
ARB were always run in parallel with ARB treated cultures,
and for the same duration. All cell lines were checked for
mycoplasma using MycoAlert assay (Cambrex Bio Sci-
ence, Rockland, ME) and found to be mycoplasma-free.
ARB was a powdered free base formulation and was dis-
solved to completion in 0.5 ml of 96-proof ethanol at
37°C for 10 min followed by dilution in 4.5 ml of sterile
distilled water. The final ethanol content in cell culture
medium was always less than 10-6 M. For each experiment
a freshly prepared stock of ARB was used. JFH-1 viral stock
preparation, cell infection and titration was performed
exactly as described [17,25]. JFH-1 plasmid was kindly
provided by Takashi Wakita. RIG-N, a constitutively active
mutant of RIG-I, was kindly provided by Michael Gale.
Cellular toxicity assay
We used the luminescence ATP detection assay system
(ATPlite, Perkin Elmer, Boston, MA) as described by the
manufacturer. Huh7, Huh7.5.1 or FL-Neo cells were
grown overnight in black 96-well view plates (104 cells per
well, 6 wells per drug concentration). After 24 h incuba-
tion with the compound the wells were washed twice with
0.2 ml of phosphate-buffered saline (PBS) followed by
addition of 0.1 ml of PBS and 50 μl of lysis solution (pro-
vided with the kit) to each well. The microplate was
shaken for 5 min at 600 rpm on an orbital shaker to allow
cell lysis and ATP stabilization. 50 μl of the substrate solu-
tion was then added, and the microplate was shaken for 5
min at 600 rpm. Luminescence was measured on a Top-
Count NXT microplate scintillation & luminescence coun-
ter (Packard; Perkin Elmer) after a 10 min dark
adaptation. The 50% cytotoxic concentration (CC50) was
determined from the dose-response curve and defined as
the drug concentration that caused a 50% signal reduction
compared to that of untreated cultures.
Western blotting
Cells grown in Costar 6-well plates (0.2 × 106 cells per
well) were lysed in 0.1 ml of RIPA buffer (50 mM tris-HCl,
pH 7.2, 150 mM NaCl, 0.1% SDS, 0.1% Na deoxycholate,
1% Triton X-100, 17.4 μg/ml PMSF). The protein lysates
were quantified using the BSA Protein Assay (Pierce Bio-Page 7 of 9
(page number not for citation purposes)
Virology Journal 2006, 3:56 http://www.virologyj.com/content/3/1/56technology, Rockford, IL). Before gel loading each sample
was adjusted to contain 10 μg of protein per gel well. Sam-
ples were mixed with equal volume of double-strength
reducing loading buffer and heated at 95°C for 7 min
before subjected to electrophoresis on a 4–20% tris-gly-
cine gel (Invitrogen). Separated proteins were transferred
to a 0.45 μm nitrocellulose membrane (Pierce) using a
semi-dry transfer system. After the transfer, the membrane
was blocked in Superblock buffer (Pierce) and incubated
with primary mouse antibody, either anti-NS5A (Biode-
sign International, Saco, ME.; 1:1000 dilution) or anti-
Core (Affinity Bioreagents, Golden, CO; 1:1000 dilution)
for 1 hr at room temperature. Both proteins were detected
on the same blot after sequential treatment with anti-
NS5A, then with anti-Core antibody, and four washes
with PBS – 0.2% Tween 20 (PBST) in between antibody
treatment. The secondary antibody was HRP-conjugated
anti-mouse immunoglobulin G (IgG) (Pierce, 1:10000
dilution). To control for comparable gel loading, the same
blot was stripped with Restore stripping buffer (Pierce),
and was re-blocked in Pierce Superblock buffer and incu-
bated overnight with goat polyclonal IgG antibody to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1:1000 in PBST. The blot was washed as above and incu-
bated with bovine anti-goat IgG-HRP (Santa Cruz Bio-
technology) diluted 1:10000 in PBST, for 1 hr at room
temperature. Protein bands were detected using chemilu-
minescence LumiGlo reagents (Cell Signaling, Danvers,
MA) and visualized after exposing the membrane against
X-ray film. Quantification of bands was performed using
ImageJ software [30].
HCV RNA quantitation
Huh7 or FL-Neo cells were seeded in Costar 6-well clusters
at 2.0 × 105 cells per well. Sub-confluent treated or
untreated cultures were lysed in 0.6 ml/well of RLT buffer
(Qiagen) containing 1% beta-mercaptoethanol. Total cel-
lular RNA was isolated using the RNeasy kit (Qiagen,
Valencia, CA) according to manufacturer's instructions.
The RNA integrity was verified by visualizing ribosomal
RNAs on 1.2% agarose gel, and total RNA concentration
was determined using RediPlate™ 96 Ribogreen RNA
quantitation Kit (Molecular Probes, Invitrogen). Ten ng of
RNA were added to wells of a 384 well plate containing
the EZ RT-PCR master mix (Perkin Elmer). Samples were
run on an ABI HT7900 real time RT-PCR machine. HCV
RNA was quantitated by real time RT-PCR, as described
[31,32]. For each run, dilutions of HCV plasmid DNA
(precisely quantitated using Invitrogen PicoGreen DNA
quantitation kit) ranging from 0–107 copies per tube,
were run in triplicate to generate a standard curve, which
served as a reference to calculate HCV RNA copy number
based on the cycle threshold (Ct). The HCV RNA copy
number was expressed as copies per 10 ng total cellular
RNA. Negative controls included reactions lacking tem-
plate as well as RNA from Huh7 cells, which were always
negative for HCV RNA.
HCV pseudoparticle (HCVpp) assay
The HCV pseusoparticle (HCVpp) system was described
in details elsewhere [14,22]. The measure of fusion
between pseudoparticles and liposomes was based upon
a lipid mixing assay, as described earlier [14]. Briefly, lipo-
somes of phosphatidylcholine/cholesterol labeled with
octadecylrhodamine (R18) (65:30:5 mol/mol) were incu-
bated at 37°C with HCVpp harboring the E1 and E2 glyc-
oproteins of HCV genotype 1b isolates AY734975 [33]
and AF333324, in the absence or presence of 1 or 6 μg/ml
ARB. Lipid mixing was initiated by decreasing the pH to
5.0 with diluted HCl, and kinetics were recorded over a
10-min period of time on an SLM Aminco 8000 spec-
trofluorimeter, at λexc 560 nm and λem 590 nm.
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ARB: arbidol; HA: hemagglutinin; HCV: hepatitis C virus;
HCVpp: HCV pseudoparticle; IFN: interferon;IFNB: IFN-
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1;NS3-4a: non-structural 3-4a; NS5A: non-structural 5A;
RT-PCR: reverse transcriptase polymerase chain reaction;
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